Nevertheless, DYRK1A’s ability to repress critical T-ALL leukemogenic pathways, such as NFAT (Catherinet et al., 2021) and NF-κB signaling (Wong et al., 2020; Grazioli et al., 2020) could help explain this phenotype. This evidence concerns the gene DYRK1A and acute lymphoblastic leukemia.